Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review.
Front Oncol
January 2025
Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Toxic epidermal necrolysis (TEN) is a rare and serious skin reaction. This study reports a case of a patient with lung adenocarcinoma (LUAD) who developed severe TEN after 8 days of treatment with Camrelizumab monotherapy. The patient's condition was effectively relieved with high-dose corticosteroids and intravenous immunoglobulin therapy.
View Article and Find Full Text PDFToxic epidermal necrolysis with thrombocytopenia induced by intravenous immunoglobulin: a case report and mini review.
J Pharm Health Care Sci
January 2025
Department of Pharmacy, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada-Cho, Kahoku-Gun, Ishikawa, 920-0293, Japan.
Background: Toxic epidermal necrolysis (TEN), a severe cutaneous hypersensitivity reaction induced particularly by drugs, is diagnosed when there is a fever of ≥ 38 °C, mucocutaneous symptoms, a rash with multiple erythema, and skin peeling of ≥ 30% of the body surface area. The mortality rate of TEN is high, and thrombocytopenia during treatment can lead to severe outcomes. Intravenous immunoglobulin (IVIg) is used when steroids are ineffective in TEN and may improve mortality; however, thrombocytopenia is a rare adverse event associated with IVIg use.
View Article and Find Full Text PDFRosacea-like skin reaction under treatment with dupilumab for atopic dermatitis.
J Dermatolog Treat
December 2025
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Purpose: Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.
Material And Methods: This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis.
Visual cues of respiratory contagion: Their impact on neuroimmune activation and mucosal immune responses in humans.
Brain Behav Immun
January 2025
Department of Biology, Neuroendocrinology and Human Biology Unit, Institute for Animal Cell- and Systems Biology, Faculty of Mathematics, Informatics and Natural Sciences, Universität Hamburg, D-22085 Hamburg, Germany. Electronic address:
This study investigated the neural correlates of perceiving visual contagion cues characteristic of respiratory infections through functional magnetic resonance imaging (fMRI). Sixty-two participants (32f/ 30 m; ∼25 years on average) watched short videos depicting either contagious or non-contagious everyday situations, while their brain activation was continuously measured. We further measured the release of secretory immunoglobulin A (sIgA) in saliva to examine the first-line defensive response of the mucosal immune system.
View Article and Find Full Text PDFSilibinin, a PLC-β3 inhibitor, inhibits mast cell activation and alleviates OVA-induced asthma.
Mol Immunol
January 2025
Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan; Master Program of Pharmaceutical Manufacture, College of Pharmacy, China Medical University, Taichung, Taiwan; Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan. Electronic address:
The immunoglobulin E (IgE) receptor FcεRI (Fc epsilon RI) plays a crucial role in allergic reactions. Recent studies have indicated that the interaction between FcεRIβ and the downstream protein phospholipase C beta 3 (PLCβ3) leads to the production of inflammatory cytokines. The aim of this study was to develop small molecules that inhibit the protein-protein interactions between FcεRIβ and PLCβ3 to treat allergic inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!